Key result
Intravenous administration of NS-2 and AFD-19 (3 mg/kg) exhibited equivalent antiarrhythmic activity to disopyramide and mexiletine (5 mg/kg) in rats with coronary occlusion.
Why the study?
Do NS-2 and AFD-19 reduce ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats compared to disopyramide and mexiletine?
Do NS-2 and AFD-19 reduce ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats compared to disopyramide and mexiletine?
NS-2 and its active metabolite AFD-19 demonstrate potent antiarrhythmic effects against ischemia-induced ventricular arrhythmias in a rat model, outperforming disopyramide and mexiletine when administered post-occlusion.
NS-2 and AFD-19 show antiarrhythmic activity in a rat occlusion model; leaves open translation to human ventricular arrhythmias.
We studied the antiarrhythmic effects of NS-2 (4-diisobutylamino-1,1-diphenyl-1-butanol maleate) and AFD-19 (active metabolite of NS-2) on early stage ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized male rats. These effects were compared with those of disopyramide and mexiletine. Drugs were intravenously administered either before or after coronary occlusion. When administered 5 min before occlusion, 3 mg/kg of NS-2 and AFD-19 exhibited equivalent anti-arrhythmic activity to that of 5 mg/kg of disopyramide and mexiletine, as assessed by reductions in the number of premature ventricular complexes and in the incidences of ventricular tachycardia and ventricular fibrillation. In a dose of 5 mg/kg, the antiarrhythmic effects of NS-2 and AFD-19 were more pronounced. When administered 5 min after coronary artery occlusion, only NS-2 and AFD-19 (in doses of 5 mg/kg) had significant antiarrhythmic effects. None of the drugs influenced the severe ventricular arrhythmias induced by reperfusion when administered 1 min before reperfusion. In conclusion, NS-2 might be effective in reducing the severity of the life-threatening ventricular arrhythmias that occur during acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Komori et al. (1994) studied Ventricular arrhythmias induced by coronary artery occlusion and reperfusion. NS-2 and AFD-19 vs. Disopyramide and mexiletine was evaluated on Reductions in the number of premature ventricular complexes and in the incidences of ventricular tachycardia and ventricular fibrillation. Intravenous administration of NS-2 and AFD-19 (3 mg/kg) exhibited equivalent antiarrhythmic activity to disopyramide and mexiletine (5 mg/kg) in rats with coronary occlusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: